The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-21
DOI
10.3389/fendo.2021.726448
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint blockade in renal cell carcinoma
- (2021) Phillip M. Rappold et al. JOURNAL OF SURGICAL ONCOLOGY
- B7-H3: an attractive target for antibody-based immunotherapy
- (2020) Filippos Kontos et al. CLINICAL CANCER RESEARCH
- Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor
- (2020) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Epigenomics of Pituitary Adenoma
- (2019) Blake M. Hauser et al. Frontiers in Endocrinology
- Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
- (2019) Michael Friedrich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
- (2019) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing's Disease
- (2019) Hanna R Kemeny et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
- (2019) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
- (2019) Nora Möhn et al. Journal of Clinical Medicine
- CLINICAL AND PATHOLOGICAL ASPECTS OF SILENT PITUITARY ADENOMAS
- (2018) Juliana Drummond et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- New horizons in tumor microenvironment biology: challenges and opportunities
- (2015) Fei Chen et al. BMC Medicine
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Incidence of Pituitary Adenomas in Northern Finland in 1992–2007
- (2010) Antti Raappana et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)
- (2009) Alberto Fernandez et al. CLINICAL ENDOCRINOLOGY
- Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas
- (2008) Roger Gejman et al. HUMAN PATHOLOGY
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search